TSHA - Taysha Gene Therapies, Inc.
About Taysha Gene Therapies, Inc. (https://www.tayshagtx.com)
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Sean Nolan | Chief Executive Officer & Chairman | 1968 | $1,189,515 USD |
| Sukumar Nagendran | President, Head of Research & Development and Director | 1967 | $1,035,020 USD |
| Kamran Alam | Chief Financial Officer & Corporate Secretary | 1978 | $741,904 USD |
| Berge Minassian | Chief Medical Advisor of UT Southwestern Gene Therapy Program | – | – |
| David McNinch | Chief Commercial Officer | 1969 | – |
| Emily McGinnis | Chief Patient & External Affairs Officer | – | – |
| Frederick Porter | Chief of Staff & Technical Operations Officer | – | – |
| Hayleigh Collins | Director of Corporate Communications & Investor Relations | – | – |
| Rumana Haque-Ahmed | Chief Regulatory Officer | – | – |
| Sean McAuliffe | Chief Business Officer | – | – |
| Steven Gray | Chief Scientific Advisor of UT Southwestern Gene Therapy Program | – | – |
| Tracy Porter | Chief People Officer | – | – |